Vijaya Diagnostic Centre operates a company-owned and company-operated network of 166 diagnostic centers (51 hubs, 115 spokes) delivering pathology and radiology under one roof, earning 92% of revenue from retail consumers with radiology contributing 37%. Hyderabad generates 67% of revenue, rest of AP-Telangana 20%, Pune 6% and West Bengal 4%, and the company is the largest player in its home market with a 40-plus year presence. Its Q1 FY27 EBITDA margin of 42.7% (up 360 bps YoY) sits far above what even exceptional operating businesses sustain, revealing structural quality: 60-70% of the cost base is fixed, blended material consumption is around 11%, leaving an approximately 89% contribution margin that converts incremental footfall almost directly into profit. Q1 FY27 PAT was INR53 crores at a 23% margin, up 37.6% YoY, with cash PAT generation close to 26-27% of revenue.
The economics persist because integration compounds wallet share in a way standalone players cannot match: 3.7 tests per patient versus 2.5-3 at typical pathology chains, and revenue per footfall of INR1,860 versus INR900-950 for pure pathology peers, all while pricing 20-25% below hospitals. Barriers are tangible rather than narrative: a four-decade brand, exclusive access to high-end equipment (the JP Nagar hub carries the first digital PET-CT with cardiac CT in Bangalore, where only one hospital has comparable technology), a pooled tele-radiology bench of 400-plus radiologists, and dense clusters that take years to replicate, evidenced by the five years taken to double the network from 81 to 162 centers since listing. The competitive structure confirms scarcity: the top-3 Hyderabad rivals are deploying capital outside the city because Vijaya holds greater share there, and Bangalore remains fragmented into locality chains of 5-6 centers with no single brand at 30-40.
The inflection is a deliberate acceleration of capital deployment. FY27 capex guidance was raised twice within six months, from INR100-120 crores in February 2026 to INR140-150 crores in May to INR190-195 crores by August, funding 9 hubs and 10-12 spokes over 12 months plus the Panjagutta automated reference laboratory and an INR8-10 crore land purchase in an AP medical hub. As of the August call, 2 hubs and 8 spokes were already live. Eighteen to twenty-four months out, the network should carry roughly 15 cumulative hubs across Pune, Bangalore and Kolkata including last year's cohort, each new hub maturing toward INR12-15 crores of annual revenue, spokes turning EBITDA-positive within 3-4 quarters of launch, and a fully automated Pune lab hub removing today's capacity constraints (existing older Pune hubs are capped at INR10-15 crores each). Wellness should rise from 14.8% of revenue toward beyond 20%, home collection launches in Bengaluru once the JP Nagar lab is accredited, and management guides high double-digit FY27 growth with 15%+ sustainable over 3-5 years.
The walk-talk record is unusually clean. Management has repeatedly guided 15%+ revenue growth and 38-40% EBITDA margins and delivered above both: FY25 revenue grew 24% (19% organic), 9M FY26 grew 17.1% with a 40.6% EBITDA margin, Q4 FY26 printed 43.5%, and Q1 FY27 came in at 42.7% against a stated 40% floor. It committed to 10 hubs in FY26 and had commissioned 9 by Q3 with INR159 crores spent against a INR150-155 crore plan; Krishnanagar and Barasat broke even in 3 quarters versus a 12-month guide, and Khammam and Nandyal in 2 quarters versus 3. FY27 guidance has been upgraded twice with nothing cut, and funding is entirely internal: approximately INR330 crores of surplus cash, maintenance capex of 2-2.5% of sales, and no indication of equity dilution.
The quantified path: if high double-digit FY27 growth holds with mature centers compounding at 16% and new centers contributing 6-6.5% of revenue, the 89% contribution margin means EBITDA grows faster than revenue, and at 26-27% cash conversion the INR190-195 crore program stays comfortably funded. Three things must hold: hub breakevens at or better than 12 months, resumption of the 1-1.5% annual tariff increase (none taken since June 2025, with reassessment flagged after Q2-Q3 FY27), and the estimated 1-1.5% expansion drag remaining contained. The falsifier to watch: the 3-4 hubs still below breakeven must keep their combined burn under INR1 crore per quarter (currently about 0.5% of revenue). If realizations stagnate while pathology mix dilutes per-test revenue and breakeven timelines stretch past a year, the 40%+ margin commitment breaks. The apparent tension between a near-doubled capex plan and rising margins is operational, not structural: the drag has been absorbed so far through cluster-level operating leverage.
companyname: Vijaya Diagnostic Centre Limited ticker: VIJAYA sector: Healthcare services – Diagnostics Vijaya Diagnostic Centre Limited is an integrated diagnostics company - it runs both radiology (imaging) and pathology (lab testing) under one roof, using a hub-and-spoke network model. It was founded in 1981 in Hyderabad and listed on the NSE and BSE in 2021. The company describes itself as India's largest B2C-focused integrated diagnostic chain (FY25 annual report), with 151 diagnostic centr...
Read the full report →capex, margin expansion, new product segment, market share gain
No guidance
Guidance upgradedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Vijaya Diagnostic Centre Limited and 4,900+ companies.
5-day free pass. No card required.